Feraccru® (Ferric Maltol) is a stable, non-salt, oral formulation of ferric iron, which has a novel mechanism of action compared to salt-based oral iron therapies. Iron can be absorbed directly from the ferric maltol molecule without dissociation with unabsorbed iron remaining as ferric maltol in the gut.
In April 2018, the European Commission (EC) adopted the decision to extend the approved indication for Feraccru® to include treatment of all adults with iron deficiency (ID) with or without anaemia. This indication provides Feraccru® with a much broader commercial opportunity.
For further information on Ferracru® please click here.
Other Ferracru® pipeline events:
Feraccru® AEGIS-H2H non-inferiority EU Phase 3b study.
The AEGIS-H2H Phase 3b study is designed as a non-inferiority trial comparing the efficacy and safety of Feraccru® to the market-leading latest generation form of IV iron(Ferinject/Injectafer, ferric carboxymaltose). Primary endpoint data from the AEGIS-H2H study is expected to be available in the second half of 2018.